Currently out of the existing stock ratings of Neena Bitritto-Garg, 39 are a HOLD (26.17%), 104 are a BUY (69.8%), 6 are a SELL (4.03%).

Neena Bitritto-Garg

Work Performance Price Targets & Ratings Chart

Analyst Neena Bitritto-Garg, carries an average stock price target met ratio of 45.87% that have a potential upside of 35.16% achieved within 180 days. Previously, Neena Bitritto-Garg worked at DEUTSCHE BANK.

Neena Bitritto-Garg’s has documented 284 price targets and ratings displayed on 25 stocks. The coverage was on the Healthcare sector.

Most recent stock forecast was given on ATAI, ATAI Life Sciences BV at 27-Mar-2026.

Wall Street Analyst Neena Bitritto-Garg

Analyst best performing recommendations are on SAGE (SAGE THERAPEUTIC).
The best stock recommendation documented was for ACAD (ACADIA PHARMACEUTICALS) at 12/12/2023. The price target of $25 was fulfilled within 1 day with a profit of $3.83 (18.09%) receiving and performance score of 180.92.

Average potential price target upside

of $51.83 (43.05%) on KRTX (KARUNA THERAPEUTICS).
of $37.51 (31.55%) on SRPT (SAREPTA THERAPEUTICS).
of $28.42 (29.3%) on NBIX (NEUROCRINE BIOSCIENCES).

ACAD ACADIA Pharmaceuticals KOD Kodiak Sciences NBIX Neurocrine Biosciences SAGE Sage Therapeutic ZGNX Zogenix LBPH Longboard Pharmaceuticals ALEC Alector AMLX Amylyx Pharmaceuticals CMPS Compass Pathways Plc KRTX Karuna Therapeutics PRTA Prothena plc ROIV Roivant Sciences Ltd SRPT Sarepta Therapeutics PASG Passage Bio ANAB AnaptysBio ARNA Arena Pharmaceuticals ATAI ATAI Life Sciences BV CRTX Cortexyme DBTX Decibel Therapeutics PRVL Prevail Therapeutics PEAR Pear Therapeutics DRTS Alpha Tau Medical Ltd LB L Brands SA Seabridge Gold ZGN Ermenegildo Zegna NV

Show more stocks

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date of last PT

Price targets met ratio

Average potential upside

Average Days to Hit Target

Performance score

Tazeen Ahmad (BAML)